Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The "PCV10 + DTaP" refers to the co-administration or fixed-dose combination of two pediatric vaccines: - **PCV10 (pneumococcal conjugate vaccine 10-valent)** protects against infections caused by ten serotypes of *Streptococcus pneumoniae*, including invasive diseases such as meningitis, bacteremia, and pneumonia. It is a protein-polysaccharide conjugate vaccine that stimulates an immune response against the bacterial polysaccharide antigens. - **DTaP (diphtheria, tetanus toxoid and acellular pertussis)** is a combined vaccine that protects against diphtheria (caused by *Corynebacterium diphtheriae*), tetanus (caused by *Clostridium tetani*), and pertussis or whooping cough (caused by *Bordetella pertussis*). The acellular component reduces side effects compared to whole-cell versions. Both vaccines are administered in early childhood as part of routine immunization schedules. They work primarily through induction of protective antibodies targeting bacterial toxins or surface components. These vaccines are often given together but may also be available in fixed-dose combinations depending on regulatory approval in different countries[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pneumococcal conjugate vaccine 10-valent + diphtheria, tetanus, and acellular pertussis vaccine.